Schering-Plough Submits Response to FDA for Saphris (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder

February 20, 2009 -- Schering-Plough Corporation today announced that it has responded to the U.S. FDA complete response letter for SAPHRIS (asenapine) sublingual tablets, which was received in January 2009.

The details can be read here.